A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors

Lithium has been the gold standard in the treatment of bipolar disorder (BPD) for 60 y. Like lithium, glycogen synthase kinase 3 (GSK-3) inhibitors display both antimanic-like and antidepressant-like effects in some animal models. However, the molecular mechanisms of both lithium and GSK-3 inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2010-06, Vol.107 (25), p.11573-11578
Hauptverfasser:	Du, Jing, Wei, Yanling, Liu, Lidong, Wang, Yun, Khairova, Rushaniya, Blumenthal, Rayah, Tragon, Tyson, Hunsberger, Joshua G, Machado-Vieira, Rodrigo, Drevets, Wayne, Wang, Yu Tian, Manji, Husseini K
Format:	Artikel
Sprache:	eng
Schlagworte:	Affect alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid - metabolism Animals Antidepressive Agents - pharmacology Bipolar Disorder - drug therapy Glycogen Synthase Kinase 3 - metabolism Glycogen Synthase Kinase 3 beta Hippocampus - metabolism Kinesin - metabolism Lithium - pharmacology Male Mice Microtubule-Associated Proteins - metabolism Models, Biological Neuronal Plasticity - drug effects Receptors, AMPA - metabolism Synapses - metabolism Thiazoles - pharmacology Urea - analogs & derivatives Urea - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!